Next Article in Journal
Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA
Previous Article in Journal
A Novel, Rapid, and Validated Stability-Indicating UPLC Method for the Estimation of Drotaverine Hydrochloride and Ibuprofen Impurities in Oral Solid Dosage Form
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Impurities in Cinacalcet Hydrochloride API and its Formulation

by
Pingili SUNIL REDDY
1,*,
Thummala Veera Raghava RAJU
1,
Penmetsa Satyanarayana RAJU
1,
Nadimpalli Sunil VARMA
1 and
Kondra Sudhakar BABU
2
1
Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad-500 072, India
2
Srikrishnadevaraya University, Anantapur-515 055, A.P., India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2015, 83(4), 583-598; https://doi.org/10.3797/scipharm.1502-06
Submission received: 25 February 2015 / Accepted: 16 April 2015 / Published: 16 April 2015

Abstract

A sensitive, stability-indicating, gradient reversed-phase ultra-performance liquid chromatography method has been developed for the quantitative estimation of cinacalcet hydrochloride impurities in active pharmaceutical ingredients and pharmaceutical formulations. Efficient chromatographic separation was achieved on an Acquity BEH Shield RP18, 100 × 2.1 mm, 1.7 µm column with the mobile phase containing pH 6.6 phosphate buffer and acetonitrile. The flow rate of the mobile phase was 0.3 mL min-1 with a column temperature of 35°C and detection wavelength at 223 nm. The relative response factor values of (+)-R-1-(1-Naphthyl)ethylamine, regioisomer, diastereomer isomer-1, and diastereomer isomer-2 were 1.79, 0.99, 0.89, and 0.88, respectively. The cinacalcet hydrochloride formulation sample was subjected to the stress conditions of acid, base, oxidative, hydrolytic, thermal, humidity, and photolytic degradation. Cinacalcet hydrochloride was found to degrade significantly under the peroxide stress conditions. The degradation products were well-resolved from cinacalcet hydrochloride and its impurities. The peak purity test results confirmed that the cinacalcet hydrochloride peak was homogenous in all stress samples and the mass balance was found to be more than 96%, thus proving the stability-indicating power of the method. The developed method was validated according to ICH guidelines.
Keywords: Cinacalcet Hydrochloride; RP-UPLC; Stability-indicating; Impurities; ICH guidelines Cinacalcet Hydrochloride; RP-UPLC; Stability-indicating; Impurities; ICH guidelines

Share and Cite

MDPI and ACS Style

REDDY, P.S.; RAJU, T.V.R.; RAJU, P.S.; VARMA, N.S.; BABU, K.S. Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Impurities in Cinacalcet Hydrochloride API and its Formulation. Sci. Pharm. 2015, 83, 583-598. https://doi.org/10.3797/scipharm.1502-06

AMA Style

REDDY PS, RAJU TVR, RAJU PS, VARMA NS, BABU KS. Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Impurities in Cinacalcet Hydrochloride API and its Formulation. Scientia Pharmaceutica. 2015; 83(4):583-598. https://doi.org/10.3797/scipharm.1502-06

Chicago/Turabian Style

REDDY, Pingili SUNIL, Thummala Veera Raghava RAJU, Penmetsa Satyanarayana RAJU, Nadimpalli Sunil VARMA, and Kondra Sudhakar BABU. 2015. "Development and Validation of a Stability-Indicating RP-UPLC Method for the Estimation of Impurities in Cinacalcet Hydrochloride API and its Formulation" Scientia Pharmaceutica 83, no. 4: 583-598. https://doi.org/10.3797/scipharm.1502-06

Article Metrics

Back to TopTop